IN-SILICO IDENTIFICATION OF SHARED MOLECULAR BIOMARKERS AND CANDIDATE THERAPEUTICS LINKING OBESITY AND CARDIOVASCULAR DISEASE USING DIFFERENTIAL GENE EXPRESSION AND PATHWAY ANALYSIS
DOI:
https://doi.org/10.4238/c9qndy02Keywords:
Obesity; cardiovascular disease; shared biomarkers; transcriptomics; differential gene expression; PIK3CG; CCR2; Ginkgolide A; Broussoflavan A; molecular docking; molecular dynamics simulation; phytochemical therapeutics.Abstract
Obesity and cardiovascular disease (CVD) are closely interconnected disorders driven by chronic inflammation, oxidative stress, endothelial dysfunction, and immune-metabolic dysregulation. However, the shared molecular biomarkers and therapeutically relevant targets linking these conditions remain insufficiently characterized. Publicly available GEO datasets were analyzed to detect differentially expressed genes (DEGs), followed by hub gene prioritization using ReactomeFI, cytoHubba, and MCODE. Functional interpretation was performed through Gene Ontology and KEGG pathway enrichment analyses. Candidate ligands with anti-inflammatory and antioxidant activity were further screened through ADMET profiling, molecular docking, molecular dynamics simulation, MM/GBSA energy estimation, and HOMO–LUMO analysis. A total of 846 downregulated and 1002 upregulated genes were identified in the CVD datasets, whereas the obesity datasets yielded 865 downregulated and 1564 upregulated genes. Integration of network-based analyses identified five shared candidate biomarkers between the two conditions: the downregulated genes JUN and EGFR, and the upregulated genes EP300, PIK3CG, and CCR2. Enrichment analysis indicated that these genes were associated with inflammation-related and signaling pathways relevant to cardiometabolic dysfunction. Among the screened phytochemicals, Ginkgolide A and Broussoflavan A showed favorable ADMET properties and emerged as the leading compounds. Docking analysis demonstrated target-dependent affinity, with Ginkgolide A showing the strongest interaction with PIK3CG (−9.3 kcal/mol) and Broussoflavan A showing the strongest interaction with CCR2 (−9.5 kcal/mol). Molecular dynamics simulation further supported these preferences, revealing greater structural stability of the PIK3CG–Ginkgolide A and CCR2–Broussoflavan A complexes over 200 ns. MM/GBSA analysis confirmed these findings, with binding free energies of −27.66 ± 1.52 kcal·mol⁻¹ for PIK3CG–Ginkgolide A and −28.72 ± 3.79 kcal·mol⁻¹ for CCR2–Broussoflavan A. Overall, this study identifies a concise shared biomarker signature linking obesity and CVD and proposes PIK3CG and CCR2 as promising therapeutic targets. The findings further suggest that Ginkgolide A and Broussoflavan A may represent potential lead compounds for the development of phytochemical-based interventions in obesity-associated cardiovascular disease.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

